Moderna's Cancer Vaccine Data Headed to ESMO Presidential Symposium, Stock Jumps 11%
MRNA has more than doubled off its 52-week low of $22.28.
Summary
Moderna announced that three abstracts on its personalized cancer vaccine intismeran autogene have been accepted for presentation at the ESMO Congress in Madrid, with Phase 3 INTerpath-001 data slated for the Presidential Symposium on October 24. The trial compares intismeran autogene plus Keytruda against Keytruda alone in adjuvant melanoma. An investor session is scheduled for the same day at 1 p.m. EDT. Shares rose 11.15% to $171.21, approaching the 52-week high of $176.66. This follows the August 19 surge when the stock jumped 150% on positive Phase 3 data for the same vaccine, and the subsequent pullback and steady climb. The ESMO presentation will provide detailed data that could further validate the vaccine's efficacy and commercial potential.
At the time of this announcement, MRNA was trading at $173.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $69.4B. The 52-week trading range was $22.28 to $176.86. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.